Alpha Cognition Inc. Common Stock (ACOG) Earnings
Alpha Cognition Inc. Common Stock is expected to report next earnings on November 12, 2026 (in NaN days), with a consensus EPS estimate of $-0.33. ACOG has beaten EPS estimates in 4 of its last 8 reported quarters (average surprise +6.7% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.39 | $-0.40 | -2.0% | $6M | +36.9% |
| May 14, 2026 | $-0.41 | $-0.37 | +9.8% | $4M | +3.2% |
| Mar 26, 2026 | $-0.27 | $-0.30 | -11.1% | $3M | -18.8% |
| Nov 13, 2025 | $-0.43 | $-0.30 | +30.2% | $3M | -46.0% |
| Aug 14, 2025 | $-0.46 | $-0.65 | -41.3% | $2M | -60.1% |
| May 15, 2025 | $-0.58 | $-0.20 | +65.5% | $3M | +485.7% |
| Mar 31, 2025 | $-0.48 | $-0.51 | -6.3% | — | — |
| Nov 14, 2024 | $-1.00 | $-0.31 | +69.0% | — | — |
| Mar 31, 2024 | — | $-0.87 | — | — | — |
| Dec 31, 2023 | — | $-1.55 | — | — | — |
| Sep 30, 2023 | — | $-0.84 | — | — | — |
| Jun 30, 2023 | — | $-0.74 | — | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 13, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Commercial Launch Progress * Zunville delivered 71% sequential net sales growth and 37% sequential unit growth (to 8,294 bottles sold) in Q2 2026, with consistent monthly sequential growth through the quarter, and June was the strongest demand month to date * Prescriber adoption: Total active HCP writers (prescribers who wrote at least one prescription) grew 27% quarter-over-quarter to 1,347, bringing cumulative life-to-date writers to 1,908, on track to hit the 2026 full-year target of ~2,000 cumulative writers; 76% of Q2 writers placed repeat prescriptions, and average productivity per writer rose to 6 prescriptions per writer, indicating deepening adoption * Nursing home penetration: Facilities with Zunville prescriptions grew 20% quarter-over-quarter to 1,095, with 346 new facilities added in the quarter; 81% of facilities with prescriptions placed repeat orders, demonstrating durable facility-level adoption * Payer access: Broad formulary activation has progressed slower than management's prior expectations, but underlying demand grew strongly without this tailwind, indicating significant clinical pull and that future formulary expansion will be pure upside * Commercial organization: The company has a right-sized, 60-person field sales organization that has completed 240+ peer-to-peer education programs since March 2026, reaching 1,058 attendees and 325 prescribers - Clinical & Evidence Generation Progress * Positive top-line results from the BEACON study were reported in Q2, demonstrating improvements in cognition, neuropsychiatric symptoms, activities of daily living (ADLs), and reductions in polypharmacy for Zunville patients; data has been submitted for presentation at upcoming medical conferences, with publications planned for fall 2026 * The Converge retrospective data review study for long-term care patients has been initiated, with top-line data expected in Q3 2026; data will add a second nursing-home-specific dataset to inform payer and provider stakeholders * The Resolve clinical study has been initiated, with sites selected, activated, and initial patient enrollment underway, expected to complete in Q2 2027 - Financial & Strategic Updates * The company completed an early settlement of its Galantos Pharma royalty obligation, simplifying its capital structure, eliminating future royalty burdens, and improving long-term Zunville franchise economics * As of June 30, 2026, the company held $41.4 million in cash and cash equivalents, with $51.5 million in working capital, which management confirms is sufficient to support the path to operating profitability targeted for 2027 * Management remains focused on disciplined capital allocation, investing only in high-return opportunities to drive growth while controlling operating costs
Guidance
- Full-year 2026 operating expense guidance was lowered from the prior range of $54 million to $58 million to a new range of $45 million to $54 million (note: corrected from transcript typo of $15 million to align with context of a downward revision from the prior range), reflecting identified efficiency opportunities that balance growth investment with disciplined expense management - Operating profitability for the full year 2027 remains the company's official target, unchanged from prior guidance - Top-line data from the Converge study is expected in Q3 2026; full Converge publications are expected to be released in 2027 - The Resolve study is expected to complete enrollment and deliver top-line data in Q2 2027 - Comparative pharmacokinetics study data for the pipeline sublingual Zunville formulation is expected in Q3 2026, which will determine the timeline for the full sublingual clinical program - Management will release 2027 expense guidance in either late Q4 2026 or early 2027; no 2027 revenue guidance has been issued yet
Segment performance
Alpha Cognition has one core commercial product segment, Zunville (Zumbel/Zenvale), an oral treatment for mild to moderate Alzheimer's disease. In Q2 2026, Zunville generated net product revenue of $6 million, representing 71% sequential quarter-over-quarter growth from $3.5 million in Q1 2026. Total company revenue for Q2 2026 was $6.1 million, up from $1.7 million in the year-ago Q2 2025. GAAP gross product margin for Zunville was 94%, with cost of goods sold of approximately $0.4 million on the $6 million in net product sales. Zunville contributed 98.4% of total company revenue in Q2 2026.
Risks & headwinds
- Payer formulary access expansion is progressing slower than management previously anticipated, which could delay faster revenue acceleration until broad coverage is secured - Inflation Reduction Act (IRA) provisions are impacting Medicare Part D plan costs, creating additional headwinds for securing new formulary coverage - The company is still in the early commercialization phase of Zunville, so long-term adherence, persistence, and sustained revenue growth have not yet been fully established - Expansion into the neurology/retail segment is contingent on both achieving operating profitability and securing broad formulary coverage, so timing of this higher-margin growth opportunity remains uncertain - Clinical trial execution could face unforeseen delays that would push back evidence generation timelines and payer engagement milestones
Analyst Q&A
Q: The analyst asked for granularity on repeat prescribing behavior, when the company will expand sales outreach beyond long-term care to neurologists, and when formulary access will become a growth tailwind. /
A: Management explained high 76% repeat rates are driven by prescribers' positive experience with Zunville's tolerability, efficacy for cognition, and improvements in behavioral symptoms, after 2-3 months of initial use. Expansion into neurology will only occur after the company achieves 2027 operating profitability and secures broad formulary coverage to avoid high retail prescription abandonment. Payer negotiations are ongoing, with the IRA increasing plan cost burdens that are slowing decisions; management still expects coverage wins in the second half of 2026, framing it as a when not if issue.
Q: The analyst asked whether Q2 sales included outsized distributor stocking, and what gross-to-net retention will be through the end of 2026 if formulary progress remains slow. /
A: Management confirmed there was no material excess stocking in Q2, as wholesalers are currently purchasing on demand, so all Q2 growth reflects pure end-user demand. Current gross-to-net retention holds steady at ~74%, and management expects this rate will remain consistent through the end of 2026 even without new formulary additions, with only minor impact from IRA-related penalties.
Q: The analyst asked what has driven continued demand momentum in early Q3 2026, and how patient adherence is trending after more than a year of launch. /
A: Management confirmed the sequential monthly growth momentum from Q2 has continued into early Q3, with no new formulary wins, so all growth comes from improved commercial targeting and execution by the 60-person sales force, meaning future formulary expansion will add pure upside. Adherence tracking is ongoing due to the unique structure of long-term care data, but management confirmed Q2 growth came from both new patient adds and ongoing refills from existing patients, with longer retention typically seen in long-term care versus retail settings.
Q: The analyst asked whether management will re-engage one-time non-repeating prescribers, or remain focused on untapped market whitespace, and what to expect for 2027 SG&A expenses after the 2026 guidance cut. /
A: Management explained many apparent one-time prescribers are actually ghostwriters with prescriptions logged under other providers, and very few providers try Zunville once and stop; most one-time prescribers move to repeat writing after 2-3 months of clinical experience, and all prescriber tiers showed improvement in Q2. Management expects SG&A levels will be broadly consistent in 2027, but full 2027 budgets are still being finalized, and guidance will be provided once completed.